Robert Dreicer, MD, MS, MACP, FASCO, presented “Perioperative Chemotherapy for Upper Tract Urothelial Cancer” at the 7th International Bladder Cancer Update on December 6, 2024, in Dallas, Texas.
How to cite: Dreicer, Robert. “Perioperative Chemotherapy for Upper Tract Urothelial Cancer” December 2024. Accessed Feb 2026. https://grandroundsinurology.com/perioperative-chemotherapy-for-upper-tract-urothelial-cancer/
Perioperative Chemotherapy for Upper Tract Urothelial Cancer – Summary
Robert Dreicer, MD, MS, MACP, FASCO, highlights the complexities of managing high-grade urothelial carcinoma of the upper tract. In this 10-minute presentation, he presents a case of a 68-year-old man with hematuria who is found to have a 2.5 cm mass at the left UPJ. After undergoing a left nephroureterectomy, pathology confirms invasive high-grade disease with lymph node involvement.
Dr. Dreicer underscores the historical challenge of interdisciplinary care in urothelial cancer management and transitions to the historical evidence for chemotherapy in urothelial cancer. He references the POUT trial, demonstrating a disease-free survival benefit with adjuvant chemotherapy.
This case illustrates the challenges in real-world decision-making, where varying recommendations reflect ongoing debates about adjuvant strategies. The talk reinforces the necessity of early multidisciplinary planning to maximize treatment opportunities.
About the 7th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Robert Dreicer, MD, MS, MACP, FASCO, is the Deputy Director and Associate Director of Clinical Research for the Cancer Center, Section Head of Solid Tumor Oncology within the School of Medicine’s Division of Hematology and Oncology, a Professor of Medicine and Urology, and the Co-Director of the Mellon Institute at the University of Virginia in Charlottesville, Virginia. Dr. Dreicer specializes in the management of genitourinary malignancies, as well as the design and conduct of clinical trials in urologic oncology. Dr. Dreicer’s research interests are in novel therapeutic approaches for urologic cancers including prostate, urothelial and kidney cancers.
